X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Sanbexin (a combination of edaravone and dexborneol) is a small molecule, sublingual tablet, which is being evaluated for the treatment of acute ischemic stroke.
Lead Product(s): Edaravone,Dexborneol
Therapeutic Area: Neurology Product Name: Sanbexin
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Neurodawn Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
Under the agreement, Simcere will develop and commercialize Connect Biopharma’s CBP-201 (rademikibart), a human monoclonal antibody against IL-4Rα, in Greater China.
Lead Product(s): Rademikibart
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Connect Biopharma
Deal Size: $141.0 million Upfront Cash: $21.0 million
Deal Type: Licensing Agreement November 21, 2023
Details:
The agreement aims to establish a mutually beneficial partnership that will advance scientific research and create new treatment options for patients with cancer, autoimmune and CNS diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Mass General Brigham
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 12, 2023
Details:
Under the agreement, MSD will supply KEYTRUDA and collaborate with Simcere to evaluate the combination of SIM0235, a potential first-in-class humanized anti-TNFR2 mAb, and MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors and CTCL.
Lead Product(s): SIM0235,Pembrolizumab
Therapeutic Area: Oncology Product Name: SIM0235
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 14, 2023
Details:
XIANNUOXIN is a combination packaged drug of a small molecule anti- SARS-CoV-2 drug candidate SSD8432 and Ritonavir, this candidate is targeted 3CL protease which is essential for SARS-CoV-2 viral replication.
Lead Product(s): SSD8432,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Xiannuoxin
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
Under the agreement, Simcere will be granted an exclusive right to develop and commercialize daridorexant (ACT-541468) in the Greater China region (Mainland China, Hong Kong, and Macau), one of the world's largest pharmaceutical markets.
Lead Product(s): Daridorexant
Therapeutic Area: Sleep Product Name: ACT-541468
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Idorsia Pharmaceuticals
Deal Size: $50.0 million Upfront Cash: $30.0 million
Deal Type: Licensing Agreement November 16, 2022
Details:
SIM0237 is an anti-PD-L1 monoclonal antibody fused with potency reduced IL-15/IL-15Rα sushi domain developed in-house by utilizing the Simcere's protein engineering platform. It can block the PD-1/PD-L1 immunosuppressive pathway via binding to PD-L1.
Lead Product(s): SIM0237
Therapeutic Area: Oncology Product Name: SIM0237
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
COSELA® (trilaciclib) is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.
Lead Product(s): Trilaciclib
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: G1 Therapeutics, Inc
Deal Size: $170.0 million Upfront Cash: $14.0 million
Deal Type: Licensing Agreement July 13, 2022
Details:
SIM0417 has shown broad-spectrum antiviral activity, good in vivo pharmacokinetic properties, and safety in pre-clinical studies. It is a highly active, low toxicity, orally administrable small molecule anti-SARS-CoV-2 drug candidate.
Lead Product(s): SIM0417
Therapeutic Area: Infections and Infectious Diseases Product Name: SIM0417
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
First-in-class (FIC) novel myelo-protective drug trilaciclib targeting large Chinese patient population receiving chemotherapy, the product has the potential for delivering significant patient impact and commercial success.
Lead Product(s): SIM0417
Therapeutic Area: Infections and Infectious Diseases Product Name: SIM0417
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
